PH12022553129A1 - Compositions and methods for treating cancer - Google Patents
Compositions and methods for treating cancerInfo
- Publication number
- PH12022553129A1 PH12022553129A1 PH1/2022/553129A PH12022553129A PH12022553129A1 PH 12022553129 A1 PH12022553129 A1 PH 12022553129A1 PH 12022553129 A PH12022553129 A PH 12022553129A PH 12022553129 A1 PH12022553129 A1 PH 12022553129A1
- Authority
- PH
- Philippines
- Prior art keywords
- methods
- compositions
- treating cancer
- chimeric binding
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/17—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063014550P | 2020-04-23 | 2020-04-23 | |
| PCT/US2021/028775 WO2021216956A1 (en) | 2020-04-23 | 2021-04-23 | Compositions and methods for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022553129A1 true PH12022553129A1 (en) | 2024-02-26 |
Family
ID=78270118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/553129A PH12022553129A1 (en) | 2020-04-23 | 2021-04-23 | Compositions and methods for treating cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230140868A1 (enExample) |
| EP (1) | EP4110822A4 (enExample) |
| JP (1) | JP7817948B2 (enExample) |
| KR (1) | KR20230019424A (enExample) |
| CN (1) | CN115485301A (enExample) |
| AU (1) | AU2021261003A1 (enExample) |
| BR (1) | BR112022019939A2 (enExample) |
| CA (1) | CA3172092A1 (enExample) |
| IL (1) | IL296576A (enExample) |
| MX (1) | MX2022013207A (enExample) |
| PH (1) | PH12022553129A1 (enExample) |
| WO (1) | WO2021216956A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020145669A1 (ko) | 2019-01-10 | 2020-07-16 | 에스지메디칼 주식회사 | 항 베타 1 인테그린 인간화 항체 및 이를 포함하는 암치료용 약학 조성물 |
| KR102423686B1 (ko) * | 2019-01-10 | 2022-07-21 | 에스지메디칼 주식회사 | 항 베타 1 인테그린 인간화 항체 및 이를 포함하는 암치료용 약학 조성물 |
| CN118284622A (zh) * | 2021-09-30 | 2024-07-02 | 阿尔法贝塔控股有限责任公司 | 治疗癌症的组合物和方法 |
| CN118542937A (zh) * | 2023-02-24 | 2024-08-27 | 恒翼生物医药(上海)股份有限公司 | 抗αvβ3抗体和抗PD-1抗体的联合药物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753230A (en) * | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
| EP0968290B1 (en) * | 1997-03-12 | 2004-12-15 | SmithKline Beecham Corporation | Anti-alphavbeta3 humanized monoclonal antibodies |
| US6160099A (en) * | 1998-11-24 | 2000-12-12 | Jonak; Zdenka Ludmila | Anti-human αv β3 and αv β5 antibodies |
| KR100983997B1 (ko) * | 2001-01-09 | 2010-09-28 | 메르크 파텐트 게엠베하 | 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를 사용하는 병용 요법 |
| EP1778726A4 (en) * | 2004-08-16 | 2009-03-18 | Medimmune Inc | INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY |
| HUE038848T2 (hu) * | 2011-04-21 | 2018-11-28 | Bristol Myers Squibb Co | CD40-antagonista antitest polipeptidek |
| BR122020002986A8 (pt) * | 2012-08-20 | 2023-04-18 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Método e composições para imunoterapia celular |
| US10150800B2 (en) * | 2013-03-15 | 2018-12-11 | Zyngenia, Inc. | EGFR-binding modular recognition domains |
| EP3113796A1 (en) * | 2014-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
| WO2017053423A1 (en) * | 2015-09-21 | 2017-03-30 | Erasmus University Medical Center | Anti-cd47 antibodies and methods of use |
| MX2019011717A (es) * | 2017-03-31 | 2019-12-16 | Univ California | Composiciones y metodos para focalizar y matar celulas madre positivas a cancer alfa-v beta-3 y tratar cancer resistentes a farmacos. |
| CN119367532A (zh) * | 2019-08-02 | 2025-01-28 | 加利福尼亚大学董事会 | 用于靶向和杀死α-vβ-3（αvβ3）阳性癌症干细胞（CSC）以及治疗耐药性和转移性癌症的组合物和方法 |
-
2021
- 2021-04-23 CA CA3172092A patent/CA3172092A1/en active Pending
- 2021-04-23 MX MX2022013207A patent/MX2022013207A/es unknown
- 2021-04-23 CN CN202180031794.6A patent/CN115485301A/zh active Pending
- 2021-04-23 AU AU2021261003A patent/AU2021261003A1/en active Pending
- 2021-04-23 BR BR112022019939A patent/BR112022019939A2/pt unknown
- 2021-04-23 PH PH1/2022/553129A patent/PH12022553129A1/en unknown
- 2021-04-23 JP JP2022564548A patent/JP7817948B2/ja active Active
- 2021-04-23 KR KR1020227040872A patent/KR20230019424A/ko active Pending
- 2021-04-23 IL IL296576A patent/IL296576A/en unknown
- 2021-04-23 EP EP21792975.1A patent/EP4110822A4/en active Pending
- 2021-04-23 WO PCT/US2021/028775 patent/WO2021216956A1/en not_active Ceased
- 2021-04-23 US US17/995,800 patent/US20230140868A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021216956A1 (en) | 2021-10-28 |
| US20230140868A1 (en) | 2023-05-11 |
| JP2023523016A (ja) | 2023-06-01 |
| CA3172092A1 (en) | 2021-10-28 |
| MX2022013207A (es) | 2023-01-24 |
| AU2021261003A1 (en) | 2022-10-20 |
| JP7817948B2 (ja) | 2026-02-19 |
| EP4110822A4 (en) | 2024-04-10 |
| KR20230019424A (ko) | 2023-02-08 |
| IL296576A (en) | 2022-11-01 |
| EP4110822A1 (en) | 2023-01-04 |
| BR112022019939A2 (pt) | 2022-12-13 |
| CN115485301A (zh) | 2022-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022553129A1 (en) | Compositions and methods for treating cancer | |
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| WO2019241802A3 (en) | Methods of inhibiting proliferative cells | |
| MX2020012130A (es) | Proteinas multiespecificas de union de direccionamiento a anhidrasa carbonica 9 (caix), anoctamina-1 (ano1), mesotelina, antigeno de superficie celular de trofoblasto (trop2), antigeno carcinoembrionario (cea) o claudina-18.2. | |
| MX2019012038A (es) | Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico. | |
| PH12022551462A1 (en) | Ilt3-binding agents and methods of use thereof | |
| PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
| MA32140B1 (fr) | Utilisation d'un anticorps anti-cd20 de type ii à cytotoxicité cellulaire accrue dépendant des anticorps (adcc) combiné au cyclophosphamide, à la vincristine et à la doxorubicine pour traiter les lymphomes non hodgkiniens | |
| WO2021262597A3 (en) | Lair-1-binding agents and methods of use thereof | |
| MX2011009220A (es) | Anticuerpos completamente humanos especificos para la molecula de adhesion celular 1. | |
| WO2021226204A3 (en) | Anti-dll3 antibodies and methods of use | |
| MX2022013259A (es) | Composiciones y metodos de tratamiento del cancer con receptores de antigeno quimerico. | |
| MX2022015475A (es) | Proteina de fusion que comprende il-12 y anticuerpo anti-fap, y uso de la misma. | |
| MX2020010323A (es) | Agentes de union al componente del complemento c3 (c3) y metodos para su uso. | |
| MX2022000853A (es) | Anticuerpos anti-liv1 humanizados para el tratamiento de cancer. | |
| MX2017015400A (es) | Inhibidores del mir-155 para tratar linfoma cutaneo de celulas t (ctcl). | |
| MX2021008834A (es) | Metodos de tratamiento del cancer de mama con tucatinib. | |
| WO2022265864A3 (en) | Tim-3 modulates anti-tumor immunity by regulating inflammasome activation | |
| MX2020000414A (es) | Composicion de vacuna de neoantigeno para el tratamiento del cancer. | |
| ZA202204730B (en) | Oligonucleotides with nucleoside analogs | |
| MX2024002753A (es) | Anticuerpos anti receptor de transferrina y usos de los mismos. | |
| MX2024014830A (es) | Compuestos de degradacion de wee1 y usos de los mismos | |
| MX2023005180A (es) | Compuestos de union a il-2r\03b2?c y usos de estos. | |
| MX2025000053A (es) | Anticuerpos monoclonales anti-slc34a2 y sus usos | |
| MX2022002607A (es) | Metodos de tratamiento. |